Company Performance - MacroGenics reported a quarterly loss of $0.65 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.61, and an improvement from a loss of $0.84 per share a year ago, indicating a surprise of -6.56% [1] - The company posted revenues of $13.19 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 5.45%, but showing an increase from $9.1 million in the same quarter last year [2] - Over the last four quarters, MacroGenics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - MacroGenics shares have declined approximately 51.1% since the beginning of the year, contrasting with the S&P 500's decline of -0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $18.13 million, and for the current fiscal year, it is -$2.21 on revenues of $78.51 million [7] Industry Outlook - The Medical - Products industry, to which MacroGenics belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The earnings outlook for MacroGenics is favorable, with a Zacks Rank of 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Core Viewpoint - Dare Bioscience, Inc. reported a quarterly loss of $0.50 per share, which was better than the Zacks Consensus Estimate of a loss of $0.63, indicating an earnings surprise of 20.63% [1] Financial Performance - The company posted revenues of $0.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 95.83%, compared to revenues of $0.01 million a year ago [2] - Over the last four quarters, the company has surpassed consensus EPS estimates four times but has not been able to beat consensus revenue estimates [2] Stock Performance - Dare Bioscience shares have lost about 7.7% since the beginning of the year, while the S&P 500 has declined by 0.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.43 on $0.6 million in revenues, and for the current fiscal year, it is -$1.97 on $3.3 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Dare Bioscience belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - Spero Therapeutics reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.55, representing an earnings surprise of 54.55% [1] - The company posted revenues of $5.87 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 46.60%, compared to revenues of $9.27 million a year ago [2] - Over the last four quarters, Spero Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Spero Therapeutics shares have declined approximately 40.8% since the beginning of the year, while the S&P 500 has only declined by 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.32 on $11 million in revenues, and for the current fiscal year, it is -$2.32 on $60 million in revenues [7] - The estimate revisions trend for Spero Therapeutics is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Spero Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Spero Therapeutics' stock performance [5]

Treace Medical Concepts (TMCI) closed the last trading session at $7.20, gaining 6.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.16 indicates a 41.1% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $2.16. While the lowest estimate of $8 indicates an 11.1% increase from the current price level, the most optimistic ana ...

Group 1 - MeiraGTx Holdings PLC reported a quarterly loss of $0.51 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.38, and an improvement from a loss of $0.77 per share a year ago, indicating a surprise of -34.21% [1] - The company generated revenues of $1.93 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 76.85%, compared to revenues of $0.7 million in the same quarter last year [2] - MeiraGTx shares have declined approximately 7.7% since the beginning of the year, while the S&P 500 has seen a decline of -0.6% [3] Group 2 - The earnings outlook for MeiraGTx is uncertain, but current consensus EPS estimates for the upcoming quarter are -$0.39 on revenues of $8.32 million, and -$0.09 on revenues of $126.94 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which MeiraGTx belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Viewpoint - Nayax reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share, but showing improvement from a loss of $0.15 per share a year ago, indicating a significant year-over-year recovery [1][2] Financial Performance - The company posted revenues of $81.11 million for the quarter ended March 2025, which was 5.29% below the Zacks Consensus Estimate and an increase from $63.96 million in the same quarter last year [2] - Over the last four quarters, Nayax has surpassed consensus EPS estimates two times but has not beaten revenue estimates during the same period [2] Stock Performance - Nayax shares have increased approximately 39.4% since the beginning of the year, contrasting with a -0.6% decline in the S&P 500 [3] - The current Zacks Rank for Nayax is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $100.62 million, while the estimate for the current fiscal year is $0.57 on revenues of $411.04 million [7] - The trend of estimate revisions for Nayax is currently mixed, which may change following the recent earnings report [6] Industry Context - The Financial Transaction Services industry, to which Nayax belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - DLocal, another company in the same industry, is expected to report quarterly earnings of $0.12 per share, reflecting a year-over-year increase of 71.4% [9]

Company Performance - Humacyte, Inc. reported a quarterly loss of $0.10 per share, better than the Zacks Consensus Estimate of a loss of $0.19, and an improvement from a loss of $0.29 per share a year ago, representing an earnings surprise of 47.37% [1] - The company posted revenues of $0.52 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.45%, compared to zero revenues a year ago [2] - Humacyte's shares have declined approximately 73.9% since the beginning of the year, contrasting with the S&P 500's decline of only 0.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $1.05 million, and for the current fiscal year, it is -$0.69 on revenues of $9.66 million [7] - The estimate revisions trend for Humacyte is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expectations of outperforming the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Humacyte belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Nuwellis, Inc. reported a quarterly loss of $0.69 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.45, representing an earnings surprise of -53.33% [1] - The company posted revenues of $1.9 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 23.84%, and showing a slight increase from $1.86 million in the same quarter last year [2] - Over the last four quarters, Nuwellis has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - Nuwellis shares have declined approximately 10.8% since the beginning of the year, contrasting with the S&P 500's decline of -0.6% [3] - The current Zacks Rank for Nuwellis is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.36 on revenues of $2.65 million, and for the current fiscal year, it is -$1.39 on revenues of $10.87 million [7] - The outlook for the Medical - Instruments industry, where Nuwellis operates, is currently in the top 31% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Group 1 - 908 Devices Inc. reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.33 per share a year ago, resulting in an earnings surprise of 18.52% [1] - The company posted revenues of $11.78 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.99%, but showing growth from $9.99 million in the same quarter last year [2] - 908 Devices shares have increased approximately 160.5% since the beginning of the year, contrasting with a decline of 0.6% in the S&P 500 [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $12.3 million, and for the current fiscal year, it is -$0.63 on revenues of $55.48 million [7] - The Medical - Instruments industry, to which 908 Devices belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8]

CyberArk (CYBR) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 24.05%. A quarter ago, it was expected that this maker of software that detects attacks on privileged accounts would post earnings of $0.71 per share when it actually produced earnings of $0.80, delivering a surprise of 1 ...